Company news

Iovance Biotherapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

August 5, 2020

Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering

June 1, 2020

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock

May 27, 2020

Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

May 26, 2020

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma

May 12, 2020

Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

May 4, 2020

Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

February 24, 2020

Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel

January 14, 2020

Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog

January 11, 2020

Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy

November 20, 2019

Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting

November 7, 2019

Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results

November 3, 2019

Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting

October 1, 2019

← Newer news releases

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 47 decks. Every deck is listed under its year.